KevinMarkSlawinMD

Minimally Invasive Surgery, Surgical Oncology, Clinical Pharmacology

Biotechnology Founder, Investor and Entrepreneur, Founder and Managing Partner, Rapha Capital Management LLC, Founder, Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), Founder and CEO, Ponce Therapeutics, Inc. (https://poncethera.com), Founder and CEO, Deliver Therapeutics, Inc. (https://deliverthera.com), Chairman and CEO, PrintBio, Inc. (https://printbio.com)

Join to view full profile

Dr. Slawin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Slawin's full profile

Already have an account?

Office
9511 Collins Avenue
#1403
Bal Harbour, FL 33154
Phone+1 305-809-6920

Fax+1 305-675-3972

Summary

No longer in practice, I manage an investment advisory in early stage biotech named Rapha Capital Management (https://raphacap.com). I’m also the Founder and CEO, Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc., both located at K2 Bio in Houston, TX, and using advanced technologies in novel ways to develop the first therapeutics to arrest or reverse aging.

Education & Training

Baylor College of MedicineFellowship, Minimally Invasive Urologic Surgery, 1992 - 1994
New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 1988 - 1992
Icahn School of Medicine at Mount SinaiResidency, Surgery, 1986 - 1988
Columbia University Vagelos College of Physicians and SurgeonsClass of 1986

Certifications & Licensure

FL State Medical License 2018 - 2025
NY State Medical License 1986 - 2022
TX State Medical License 1993 - 2019

Awards, Honors, & Recognition

F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology. Scott Dept. of Urology, Baylor College of Medicine, 2003
America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Join now to see all

Clinical Trials

Medical Therapy of Prostatic Symptoms Start of enrollment: 1995 Dec 01
Completed
Phase 3
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology Start of enrollment: 2012 Aug 01
Completed
Phase 2

Publications & Presentations

PubMed

65 citations
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
Stacy Loeb, Sanghyuk S. Shin, Dennis L. Broyles, John T. Wei, Martin G. Sanda
BJU International. 2017-07-01
333 citations
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in th...
William J. Catalona, Alan W. Partin, Martin G. Sanda, John T. Wei, George G. Klee
The Journal of Urology. 2011-05-01
188 citations
The prostate health index selectively identifies clinically significant prostate cancer
Stacy Loeb, Martin G. Sanda, Dennis L. Broyles, Sanghyuk S. Shin, Chris H. Bangma
The Journal of Urology. 2015-04-01

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-S...
John P Mulhall, Eric A Klein, Kevin Slawin, Peter T Scardino, The Journal of Sexual Medicine

Press Mentions

Rapha Capital Management Launches $100M Life Science VC Fund with an Eye on Early ScienceApril 16th, 2021
AHA, Children’s Heart Foundation Award Funds to Research in Congenital Heart DefectsFebruary 13th, 2021
Biopharmaceutical Company AsclepiX Therapeutics Raises $35 MillionJune 29th, 2020
Join now to see all